Who is sponsoring NCT02068365?

NCT02068365 is sponsored by Chinese University of Hong Kong.

What condition does NCT02068365 study?

NCT02068365 studies Chronic Hepaititis B.

What drugs are being tested in NCT02068365?

Interventions: Pegyinterferon-alfa-2a.

What is the status of NCT02068365?

NCT02068365 is currently COMPLETED.

Last reviewed 2019-07-29 · How we verify

An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

NCT02068365 Phase 4 COMPLETED

This is a multi-center, single-arm, open-label study on the virological response of chronic HBV infection to pegyinterferon-alfa-2a among patients who achieved HBeAg seroconversion on nucleos(t)ide analogue (NA) treatment. The primary endpoint of this study is to investigate the sustained response (HBeAg seroconversion with HBV DNA \<2000 IU/ml) to peginterferon at 24 weeks after the end of treatment.

Details

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 4
Status	COMPLETED
Enrolment	41
Start date	2013-06
Completion	2019-06

Conditions

Chronic Hepaititis B

Interventions

Pegyinterferon-alfa-2a

Primary outcomes

Sustained response (HBeAg seroconversion and HBV DNA <2000 IU/ml) — 24 weeks post-treatment

Countries

Hong Kong